{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:23:37Z","timestamp":1791894217420,"version":"4.3.4"},"reference-count":105,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,31]],"date-time":"2022-08-31T00:00:00Z","timestamp":1661904000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Vitiligo, whose treatment remains a serious concern and challenge, is an autoimmune skin disease characterized by patches of depigmentation. The increasing application of molecular-targeted therapy in skin diseases, such as psoriasis and systemic lupus erythematosus, has dramatically improved their condition. Besides, there is a favorable effect of repigmentation in the treatment of the above diseases combined with vitiligo, implying that molecular-targeted therapy may also have utility in vitiligo treatment. Recently, the role of cytokine and signaling pathways in vitiligo pathogenesis are increasingly recognized. Thus, investigations are underway targeting the molecules described above. In this paper, we present a synopsis of current practices in vitiligo treatment and introduce the improvement in identifying new molecular targets and applying molecular-targeted therapies, including those under development in vitiligo treatment, providing valuable insight into establishing further precision medicine for vitiligo patients.<\/jats:p>","DOI":"10.3389\/fimmu.2022.986918","type":"journal-article","created":{"date-parts":[[2022,8,31]],"date-time":"2022-08-31T08:30:01Z","timestamp":1661934601000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":88,"title":["Advances in vitiligo: Update on therapeutic targets"],"prefix":"10.3389","volume":"13","author":[{"given":"Yifei","family":"Feng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/S0140-6736(14)60763-7","article-title":"Vitiligo","volume":"386","author":"Ezzedine","year":"2015","journal-title":"Lancet (London England)"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-020-02108-8","article-title":"\u201cOral mycophenolate mofetil as a stabilizing treatment for progressive non-segmental vitiligo: results from a prospective, randomized, investigator-blinded pilot study\u201d","volume":"313","author":"Bishnoi","year":"2021","journal-title":"Arch Dermatol Res"},{"key":"B3","article-title":"\u201cLow-dose methotrexate for vitiligo\u201d","volume":"16","author":"Garza-Mayers","year":"2017","journal-title":"Drugs Dermatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1159\/000433424","article-title":"A randomized comparative study of oral corticosteroid minipulse and low-dose oral methotrexate in the treatment of unstable vitiligo","volume":"231","author":"Singh","year":"2015","journal-title":"Dermatology"},{"key":"B5","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/j.1365-2133.2012.11197.x","article-title":"Guidelines for the management of vitiligo: The European dermatology forum consensus","volume":"168","author":"Taieb","year":"2013","journal-title":"Br J Dermatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2019.0696","article-title":"Treatment outcomes of topical calcineurin inhibitor therapy for patients with vitiligo: A systematic review and meta-analysis","volume":"155","author":"Lee","year":"2019","journal-title":"JAMA Dermatol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s40257-015-0164-2","article-title":"Efficacy and safety of 308-nm monochromatic excimer lamp versus other phototherapy devices for vitiligo: A systematic review with meta-analysis","volume":"17","author":"Lopes","year":"2016","journal-title":"Am J Clin Dermatol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.det.2019.08.005","article-title":"Phototherapy for vitiligo","volume":"38","author":"Zubair","year":"2020","journal-title":"Dermatol Clinics"},{"key":"B9","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.det.2016.11.009","article-title":"Surgical therapies for vitiligo","volume":"35","author":"Mohammad","year":"2017","journal-title":"Dermatol Clinics"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.12.041","article-title":"The vitiligo working group recommendations for narrowband ultraviolet b light phototherapy treatment of vitiligo","volume":"76","author":"Mohammad","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B11","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.det.2016.11.010","article-title":"Depigmentation therapies for vitiligo","volume":"35","author":"Grimes","year":"2017","journal-title":"Dermatol Clinics"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1470.2009.00978.x","article-title":"Childhood vitiligo: A long-term study of localized vitiligo treated by noncultured cellular grafting","volume":"27","author":"Mulekar","year":"2010","journal-title":"Pediatr Dermatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.140.10.1211","article-title":"Long-term follow-up study of segmental and focal vitiligo treated by autologous, noncultured melanocyte-keratinocyte cell transplantation","volume":"140","author":"Mulekar","year":"2004","journal-title":"Arch Dermatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.14713","article-title":"S1 guideline: Diagnosis and therapy of vitiligo","volume":"20","author":"Bohm","year":"2022","journal-title":"J Dtsch Dermatol Ges"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta24640","article-title":"Home-based narrowband UVB, topical corticosteroid or combination for children and adults with vitiligo: HI-light vitiligo three-arm RCT","volume":"24","author":"Batchelor","year":"2020","journal-title":"Health Technol Assess"},{"key":"B16","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/phpp.12277","article-title":"Effect of narrow band ultraviolet b phototherapy as monotherapy or combination therapy for vitiligo: A meta-analysis","volume":"33","author":"Li","year":"2017","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2011.463","article-title":"A mouse model of vitiligo with focused epidermal depigmentation requires IFN-gamma for autoreactive CD8(+) T-cell accumulation in the skin","volume":"132","author":"Harris","year":"2012","journal-title":"J Invest Dermatol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"223ra23","DOI":"10.1126\/scitranslmed.3007811","article-title":"CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo","volume":"6","author":"Rashighi","year":"2014","journal-title":"Sci Trans Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.10.048","article-title":"CXCR3 depleting antibodies prevent and reverse vitiligo in mice","volume":"137","author":"Richmond","year":"2017","journal-title":"J Invest Dermatol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.06.186","article-title":"HSP70iQ435A-encoding DNA repigments vitiligo lesions in Sinclair swine","volume":"138","author":"Henning","year":"2018","journal-title":"J Invest Dermatol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"eaam7710","DOI":"10.1126\/scitranslmed.aam7710","article-title":"Antibody blockade of IL-15 signaling has the potential to durably reverse vitiligo","volume":"10","author":"Richmond","year":"2018","journal-title":"Sci Trans Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/exd.13773","article-title":"Role of IL-17A receptor blocking in melanocyte survival: A strategic intervention against vitiligo","volume":"28","author":"Bhardwaj","year":"2019","journal-title":"Exp Dermatol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2017.07.009","article-title":"Effective use of ustekinumab in a patient with concomitant psoriasis, vitiligo, and alopecia areata","volume":"3","author":"Elkady","year":"2017","journal-title":"JAAD Case Rep"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1159\/000112932","article-title":"Vitiligo improvement in a patient with ankylosing spondylitis treated with infliximab","volume":"216","author":"Simon","year":"2008","journal-title":"Dermatology"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12168","article-title":"Treatment of vitiligo with a chimeric monoclonal antibody to CD20: A pilot study","volume":"174","author":"Ruiz-Arguelles","year":"2013","journal-title":"Clin Exp Immunol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1038\/s41598-018-19407-w","article-title":"PD-L1 reverses depigmentation in pmel-1 vitiligo mice by increasing the abundance of tregs in the skin","volume":"8","author":"Miao","year":"2018","journal-title":"Sci Rep"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2020.06.003","article-title":"SFRP5 inhibits melanin synthesis of melanocytes in vitiligo by suppressing the wnt\/beta-catenin signaling","volume":"8","author":"Zou","year":"2021","journal-title":"Genes Dis"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.00963","article-title":"The JAK\/STAT signaling pathway","volume":"117","author":"Rawlings","year":"2004","journal-title":"J Cell Sci"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/med.21426","article-title":"Trends in regenerative medicine: Repigmentation in vitiligo through melanocyte stem cell mobilization","volume":"37","author":"Birlea","year":"2017","journal-title":"Med Res Rev"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.05.043","article-title":"Repigmentation in vitiligo using the janus kinase inhibitor tofacitinib may require concomitant light exposure","volume":"77","author":"Liu","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/ced.13290","article-title":"Oral tofacitinib: A promising treatment in atopic dermatitis, alopecia areata and vitiligo","volume":"42","author":"Vu","year":"2017","journal-title":"Clin Exp Dermatol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18606","article-title":"Open-label pilot study of tofacitinib 2% for the treatment of refractory vitiligo","volume":"182","author":"Mobasher","year":"2020","journal-title":"Br J Dermatol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-0653","article-title":"U.S. food and drug administration approval: ruxolitinib for the treatment of patients with intermediate and high-risk myelofibrosis","volume":"18","author":"Deisseroth","year":"2012","journal-title":"Clin Cancer Res"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-03-484642","article-title":"The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo","volume":"122","author":"Heine","year":"2013","journal-title":"Blood"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30609-7","article-title":"Ruxolitinib cream for treatment of vitiligo: A randomised, controlled, phase 2 trial","volume":"396","author":"Rosmarin","year":"2020","journal-title":"Lancet"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.02.049","article-title":"Treatment of vitiligo with the topical janus kinase inhibitor ruxolitinib","volume":"76","author":"Rothstein","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3889\/oamjms.2018.042","article-title":"Micro - focused phototherapy associated to janus kinase inhibitor: A promising valid therapeutic option for patients with localized vitiligo","volume":"6","author":"Gianfaldoni","year":"2018","journal-title":"Open Access Maced J Med Sci"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2014.918604","article-title":"Selective JAK inhibitors in development for rheumatoid arthritis","volume":"23","author":"Norman","year":"2014","journal-title":"Expert Opin Investig Drugs"},{"key":"B39","unstructured":"A study of ATI-50002 topical solution for the treatment of vitiligo2018"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1002\/art.41316","article-title":"Efficacy and safety of PF-06651600 (Ritlecitinib), a novel JAK3\/TEC inhibitor, in patients with moderate-to-Severe rheumatoid arthritis and an inadequate response to methotrexate","volume":"72","author":"Robinson","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"B41","unstructured":"A phase 2b study to evaluate the efficacy and safety profile of PF-06651600 and PF-06700841 in active non-segmental vitiligo subjects2018"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.114.218164","article-title":"The novel kinase inhibitor PRT062070 (Cerdulatinib) demonstrates efficacy in models of autoimmunity and b-cell cancer","volume":"351","author":"Coffey","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2015.335","article-title":"Transcriptional analysis of vitiligo skin reveals the alteration of WNT pathway: A promising target for repigmenting vitiligo patients","volume":"135","author":"Regazzetti","year":"2015","journal-title":"J Invest Dermatol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2015.372","article-title":"Melanocyte regeneration in vitiligo requires WNT beneath their wings","volume":"135","author":"Harris","year":"2015","journal-title":"J Invest Dermatol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2013.235","article-title":"Wnt\/beta-catenin and kit signaling sequentially regulate melanocyte stem cell differentiation in UVB-induced epidermal pigmentation","volume":"133","author":"Yamada","year":"2013","journal-title":"J Invest Dermatol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1089\/scd.2021.0276","article-title":"Micro-injury induces hair regeneration and vitiligo repigmentation through wnt\/\u03b2-catenin pathway","author":"Han","year":"2022","journal-title":"Stem Cells Dev"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2021.105582","article-title":"Design, synthesis and structure-activity relationship optimization of phenanthridine derivatives as new anti-vitiligo compounds","volume":"119","author":"Yang","year":"2022","journal-title":"Bioorg Chem"},{"key":"B48","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/nature07242","article-title":"The impact of microRNAs on protein output","volume":"455","author":"Baek","year":"2008","journal-title":"Nature"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.5021\/ad.2020.32.6.441","article-title":"The role of MicroRNAs in vitiligo: Regulators and therapeutic targets","volume":"32","author":"Li","year":"2020","journal-title":"Ann Dermatol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3892\/mmr.2020.11689","article-title":"MicroRNA215p protects melanocytes via targeting STAT3 and modulating Treg\/Teff balance to alleviate vitiligo","volume":"23","author":"Huo","year":"2021","journal-title":"Mol Med Rep"},{"key":"B51","doi-asserted-by":"publisher","first-page":"10079","DOI":"10.1038\/s41598-019-46529-6","article-title":"Micro RNAs upregulated in vitiligo skin play an important role in its aetiopathogenesis by altering TRP1 expression and keratinocyte-melanocytes cross-talk","volume":"9","author":"Vaish","year":"2019","journal-title":"Sci Rep"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.15864","article-title":"Down-regulation of exosomal miR-200c derived from keratinocytes in vitiligo lesions suppresses melanogenesis","volume":"24","author":"Zhao","year":"2020","journal-title":"J Cell Mol Med"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2021.663091","article-title":"Identification of a potentially functional circRNA-miRNA-mRNA regulatory network in melanocytes for investigating pathogenesis of vitiligo","volume":"12","author":"Li","year":"2021","journal-title":"Front Genet"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13886","article-title":"Altered expression of four miRNA (miR-1238-3p, miR-202-3p, miR-630 and miR-766-3p) and their potential targets in peripheral blood from vitiligo patients","volume":"44","author":"Shang","year":"2017","journal-title":"J Dermatol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1042\/CS20140005","article-title":"Targeted delivery of miRNA therapeutics for cardiovascular diseases: opportunities and challenges","volume":"127","author":"Kwekkeboom","year":"2014","journal-title":"Clin Sci (Lond)"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2018.08.011","article-title":"Effect of silencing microRNA-508 by STTM on melanogenesis in alpaca (Vicugna pacos)","volume":"678","author":"Liu","year":"2018","journal-title":"Gene"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2019.10492","article-title":"Knockdown of microRNA1435p by STTM technology affects eumelanin and pheomelanin production in melanocytes","volume":"20","author":"Qi","year":"2019","journal-title":"Mol Med Rep"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3892\/ijmm.2020.4478","article-title":"Role of the p53\u2212TRPM1\/miR\u2212211\u2212MMP9 axis in UVB\u2212induced human melanocyte migration and its potential in repigmentation","volume":"45","author":"Su","year":"2020","journal-title":"Int J Mol Med"},{"key":"B59","doi-asserted-by":"crossref","DOI":"10.1084\/jem.193.11.1295","article-title":"Human cd25(+)cd4(+) t regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function","volume":"193","author":"Levings","year":"2001","journal-title":"J Exp Med"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-148X.2010.00688.x","article-title":"Reduced skin homing by functional treg in vitiligo","volume":"23","author":"Klarquist","year":"2010","journal-title":"Pigment Cell Melanoma Res"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2013.540","article-title":"A quantitative increase in regulatory T cells controls development of vitiligo","volume":"134","author":"Chatterjee","year":"2014","journal-title":"J Invest Dermatol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2020.104214","article-title":"Identification, selection, and expansion of non-gene modified alloantigen-reactive tregs for clinical therapeutic use","volume":"357","author":"Alzhrani","year":"2020","journal-title":"Cell Immunol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.581433","article-title":"Antigen specificity enhances disease control by tregs in vitiligo","volume":"11","author":"Mukhatayev","year":"2020","journal-title":"Front Immunol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2015.26","article-title":"CCL22 to activate treg migration and suppress depigmentation in vitiligo","volume":"135","author":"Eby","year":"2015","journal-title":"J Invest Dermatol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.13723","article-title":"HO-1 regulates the function of treg: Association with the immune intolerance in vitiligo","volume":"22","author":"Zhang","year":"2018","journal-title":"J Cell Mol Med"},{"key":"B66","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.jid.2019.08.435","article-title":"Antibiotics drive microbial imbalance and vitiligo development in mice","volume":"140","author":"Dellacecca","year":"2020","journal-title":"J Invest Dermatol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2010.09.002","article-title":"The mammalian target of rapamycin: linking T cell differentiation, function, and metabolism","volume":"33","author":"Powell","year":"2010","journal-title":"Immunity"},{"key":"B68","unstructured":"2022"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2021.1872342","article-title":"Polymeric nanoparticles containing rapamycin and autoantigen induce antigen-specific immunological tolerance for preventing vitiligo in mice","volume":"17","author":"Zhang","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1111\/imm.13538","article-title":"Calcium controlled NFATc1 activation enhances suppressive capacity of regulatory T cells isolated from generalized vitiligo patients","author":"Giri","year":"2022","journal-title":"Immunology"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-2080","article-title":"Interferon-gamma inhibits melanogenesis and induces apoptosis in melanocytes: A pivotal role of CD8+ cytotoxic T lymphocytes in vitiligo","volume":"95","author":"Yang","year":"2015","journal-title":"Acta Derm Venereol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1111\/pcmr.12559","article-title":"Differential expression of CXCL9, CXCL10, and IFN-gamma in vitiligo and alopecia areata patients","volume":"30","author":"Maouia","year":"2017","journal-title":"Pigment Cell Melanoma Res"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2011.377","article-title":"IFN-gamma, IL-21, and IL-10 co-expression in evolving autoimmune vitiligo lesions of smyth line chickens","volume":"132","author":"Shi","year":"2012","journal-title":"J Invest Dermatol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1586\/1744666X.1.1.11","article-title":"Anticytokine therapy, particularly anti-IFN-gamma, in Th1-mediated autoimmune diseases","volume":"1","author":"Skurkovich","year":"2005","journal-title":"Expert Rev Clin Immunol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"4930","DOI":"10.1038\/s41598-020-61931-1","article-title":"GPNMB is expressed in human epidermal keratinocytes but disappears in the vitiligo lesional skin","volume":"10","author":"Biswas","year":"2020","journal-title":"Sci Rep"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2017.08.038","article-title":"Vitiligo skin is imprinted with resident memory CD8 T cells expressing CXCR3","volume":"138","author":"Boniface","year":"2018","journal-title":"J Invest Dermatol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1111\/j.1755-148X.2011.00916.x","article-title":"HSP70i is a critical component of the immune response leading to vitiligo","volume":"25","author":"Mosenson","year":"2012","journal-title":"Pigment Cell melanoma Res"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.4103\/0019-5154.185704","article-title":"Heat shock protein-70 expression in vitiligo and its relation to the disease activity","volume":"61","author":"Doss","year":"2016","journal-title":"Indian J Dermatol"},{"key":"B79","doi-asserted-by":"publisher","first-page":"174ra28","DOI":"10.1126\/scitranslmed.3005127","article-title":"Mutant HSP70 reverses autoimmune depigmentation in vitiligo","volume":"5","author":"Mosenson","year":"2013","journal-title":"Sci Transl Med"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.618897","article-title":"Pathophysiology of skin resident memory T cells","volume":"11","author":"Tokura","year":"2020","journal-title":"Front Immunol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.10.032","article-title":"Resident memory and recirculating memory T cells cooperate to maintain disease in a mouse model of vitiligo","volume":"139","author":"Richmond","year":"2019","journal-title":"J Invest Dermatol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.freeradbiomed.2019.05.011","article-title":"Oxidative stress-induced IL-15 trans-presentation in keratinocytes contributes to CD8(+) T cells activation via JAK-STAT pathway in vitiligo","volume":"139","author":"Chen","year":"2019","journal-title":"Free Radic Biol Med"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.13908","article-title":"Elevated serum level of interleukin-15 in vitiligo patients and its correlation with disease severity but not activity","volume":"20","author":"Atwa","year":"2021","journal-title":"J Cosmet Dermatol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-18-3134","article-title":"Upregulation of PD-L1 via HMGB1-activated IRF3 and NF-kappaB contributes to UV radiation-induced immune suppression","volume":"79","author":"Wang","year":"2019","journal-title":"Cancer Res"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-148X.2011.00945.x","article-title":"Dysregulation of melanocyte function by Th17-related cytokines: significance of Th17 cell infiltration in autoimmune vitiligo vulgaris","volume":"25","author":"Kotobuki","year":"2012","journal-title":"Pigment Cell Melanoma Res"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2010.03972.x","article-title":"Role of interleukin-17 in the pathogenesis of vitiligo","volume":"36","author":"Bassiouny","year":"2011","journal-title":"Clin Exp Dermatol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.12392","article-title":"Increased serum levels of interleukin-23 circulating in patients with non-segmental generalized vitiligo","volume":"54","author":"Vaccaro","year":"2015","journal-title":"Int J Dermatol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1111\/exd.12369","article-title":"T helper 17 and tregs: A novel proposed mechanism for NB-UVB in vitiligo","volume":"23","author":"Hegazy","year":"2014","journal-title":"Exp Dermatol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1111\/pcmr.12789","article-title":"IL-17A is not a treatment target in progressive vitiligo","volume":"32","author":"Speeckaert","year":"2019","journal-title":"Pigment Cell melanoma Res"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2006.02744.x","article-title":"Increased tumor necrosis factor alpha (TNF-alpha) and interleukin 1 alpha (IL1-alpha) levels in the lesional skin of patients with nonsegmental vitiligo","volume":"45","author":"Birol","year":"2006","journal-title":"Int J Dermatol"},{"key":"B91","doi-asserted-by":"crossref","DOI":"10.1038\/nri2761","article-title":"Therapeutic antibodies for autoimmunity and inflammation","volume":"10","author":"Chan","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"B92","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/keq031","article-title":"Transmembrane TNF-\u03b1: structure, function and interaction with anti-TNF agents","volume":"49","author":"Horiuchi","year":"2010","journal-title":"Rheumatology"},{"key":"B93","article-title":"Etanercept (Enbrel): update on therapeutic use","year":"2000","journal-title":"Ann Rheum Dis"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14016","article-title":"Tumour necrosis factor-\u03b1 inhibition can stabilize disease in progressive vitiligo","volume":"173","author":"Webb","year":"2015","journal-title":"Br J Dermatol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2017.11.012","article-title":"Increased risk of vitiligo following anti-tumor necrosis factor therapy: A 10-year population-based cohort study","volume":"138","author":"Bae","year":"2018","journal-title":"J Invest Dermatol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1016\/j.annder.2013.09.158","article-title":"[Occurrence of vitiligo in a patient with ankylosing spondylitis receiving adalimumab]","volume":"140","author":"Toussirot","year":"2013","journal-title":"Ann Dermatol Venereol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.5021\/ad.2015.27.5.620","article-title":"Development of vitiligo during treatment with adalimumab: A plausible or paradoxical response?\"","volume":"27","author":"Jung","year":"2015","journal-title":"Ann Dermatol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.5021\/ad.2017.29.6.826","article-title":"A type II segmental vitiligo developed under infliximab treatment for ulcerative colitis","volume":"29","author":"Ryu","year":"2017","journal-title":"Ann Dermatol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.05.035","article-title":"Vitiligo after the resolution of psoriatic plaques during treatment with adalimumab","volume":"58","author":"Smith","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1590\/abd1806-4841.20142887","article-title":"Segmental vitiligo after infliximab use for rheumatoid arthritis\u2013a case report","volume":"89","author":"Carvalho","year":"2014","journal-title":"Anais bras dermatol"},{"key":"B101","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/s0065-2776(08)60876-7","article-title":"Human b lymphocytes: phenotype, proliferation, and differentiation","volume":"52","author":"Banchereau","year":"1992","journal-title":"Adv Immunol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1016\/j.mehy.2010.10.034","article-title":"Possible roles of b lymphocyte activating factor of the tumour necrosis factor family in vitiligo autoimmunity","volume":"76","author":"Lin","year":"2011","journal-title":"Med Hypotheses"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1038\/ncprheum0042","article-title":"B-cell targeted therapies in rheumatoid arthritis and systemic lupus erythematosus","volume":"2","author":"Eisenberg","year":"2006","journal-title":"Nat Clin Pract Rheumatol"},{"key":"B104","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1136\/pmj.78.924.599","article-title":"Current concepts for the management of systemic lupus erythematosus in adults: A therapeutic challenge","volume":"78","author":"Ioannou","year":"2002","journal-title":"Postgrad Med J"},{"key":"B105","unstructured":"Open-label pilot study of abatacept for the treatment of vitiligo"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.986918\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,31]],"date-time":"2022-08-31T08:30:09Z","timestamp":1661934609000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.986918\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,31]]},"references-count":105,"alternative-id":["10.3389\/fimmu.2022.986918"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.986918","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,31]]},"article-number":"986918"}}